Lipid changes and tolerability in a cohort of adult HIV-infected patients who switched to rilpivirine/emtricitabine/tenofovir due to intolerance to previous combination ART: the PRO-STR study.
J Antimicrob Chemother
; 73(8): 2171-2176, 2018 08 01.
Article
en En
| MEDLINE
| ID: mdl-29788066
ABSTRACT
Objectives:
To analyse lipid changes and tolerability in a cohort of HIV-infected patients who switched their antiretroviral regimens to rilpivirine/emtricitabine/tenofovir (RPV/FTC/TDF) in a real-world setting.Methods:
PRO-STR is a 48 week prospective observational post-authorization study in 25 hospitals. Patients with a viral load <1000 copies/mL, receiving at least 12 months of combination ART (cART), with constant posology for at least the prior 3 months, were categorized according to previous treatment [NNRTI or ritonavir-boosted PI (PI/r)]. Analytical tests were performed at the baseline visit, between week 16 and week 32, and at week 48.Results:
A total of 303 patients were included (mean age 46.6 years; male 74.0%; previous treatment 74.7% NNRTI and 25.3% PI/r). Both groups exhibited significantly reduced lipid profiles, except for HDL cholesterol, for which a non-significant increase was observed. [NNRTI patients total cholesterol (baseline 195.5â±â38.4 mg/dL; week 48 171.0â±â35.5 mg/dL), total cholesterol/HDL ratio (baseline 4.2â±â1.2; week 48 4.0â±â1.2), HDL (baseline 49.1â±â12.0 mg/dL; week 48 49.2â±â45.8 mg/dL), LDL (baseline 119.2â±â30.2 mg/dL; week 48 114.2â±â110.7 mg/dL), and triglycerides (baseline 136.6â±â86.8 mg/dL; week 48 113.4â±â67.8 mg/dL); PI/r patients total cholesterol (baseline 203.2â±â48.8 mg/dL; week 48 173.4â±â36.9 mg/dL), total cholesterol/HDL ratio (baseline 4.7â±â1.6; week 48 4.0â±â1.2), HDL (baseline 46.4â±â12.5 mg/dL; week 48 52.1â±â54.4 mg/dL), LDL (baseline 127.0â±â36.3 mg/dL; week 48 111.4â±â35.8 mg/dL), and triglycerides (baseline 167.6â±â107.7 mg/dL; week 48 122.7â±â72.1 mg/dL)]. The most common intolerances were neuropsychiatric in the NNRTI patients and gastrointestinal and metabolic in the PI/r patients, and these intolerances were significantly reduced in both groups at week 48 [NNRTI neuropsychiatric (baseline 81.3%; week 48 0.0%); PI/r gastrointestinal (baseline 48.7%; week 48 0.0%) and metabolic (baseline 42.1%; week 48 0.0%)].Conclusions:
RPV/FTC/TDF improved the lipid profiles and reduced the intolerances after switching from NNRTI or PI-based regimens, in a cohort of HIV-infected patients.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Infecciones por VIH
/
Fármacos Anti-VIH
/
Terapia Antirretroviral Altamente Activa
/
Dislipidemias
/
Sustitución de Medicamentos
/
Lípidos
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Observational_studies
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Antimicrob Chemother
Año:
2018
Tipo del documento:
Article
País de afiliación:
España